Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Lixte Biotechnology Holdings ( (LIXT) ) is now available.
On February 12 and 13, 2026, Lixte Biotechnology Holdings and its subsidiary Liora Technologies Europe entered into an Allocation Deed and Consultancy Agreement with healthcare industry veteran Sidney Braun, appointing him to Liora’s board and as its Chief Executive Officer. Braun will receive a signing bonus, a monthly retainer and a 20% share of the net purchase price in the event of a sale of Liora or any successor, aligning his incentives with the subsidiary’s strategic and transactional outcomes.
On February 18, 2026, Lixte announced Braun’s appointment as CEO of Liora, highlighting his role in creating Liora and facilitating Lixte’s November 2025 acquisition of its assets from Orbit Capital. The move is intended to accelerate development and scaling of Liora’s LiGHT proton therapy system, support Lixte’s ambition to build a recurring revenue model in cancer radiotherapy and strengthen the company’s positioning in advanced oncology treatment technologies for patients and shareholders.
More about Lixte Biotechnology Holdings
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on developing and commercializing new cancer therapies, including its lead PP2A inhibitor LB-100, which aims to enhance chemo- and immunotherapies. Through wholly owned subsidiary Liora Technologies Europe Ltd., the company is also advancing electronically controlled proton therapy systems, led by its LiGHT System technology for treating tumors across various cancers.
Lixte’s approach is supported by a broad patent portfolio and proof-of-concept clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma, positioning the company in emerging fields of cancer biology and radiotherapy technology. Liora’s LiGHT System is intended to offer advantages over current proton therapy solutions, underscoring Lixte’s dual focus on pharmaceuticals and oncology-focused med-tech innovation.
Average Trading Volume: 94,253
Technical Sentiment Signal: Sell
Current Market Cap: $24.44M
Learn more about LIXT stock on TipRanks’ Stock Analysis page.